Bracing for a pandemic winter, Biogen's fortune at the FDA, and remembering a remarkable 12-year-old
How bad will this winter be? Is everything coming up Biogen? And who's going to be president on Jan. 20? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podca...
5 Marras 202026min
Episode 135: Pfizer's Covid-19 mystery, Ashish Jha on pandemic response, & STAT turns 5
When are we getting Covid-19 vaccine data? Will concerts ever be safe again? And what's a "Bionomy"?
29 Loka 202029min
Episode 134: Erik Gordon on SPACs, plus Covid-19 vaccines, & Biogen's case in Alzheimer's
Who's voice rings loudest at the FDA? Is it wise to give hedge funds a blank check? And how will the Biogen saga end?
22 Loka 202024min
Episode 133: A week of pauses, pharma’s statehouse spending, & how HBCUs approach Covid-19 trials
Is your local lawmaker flush with pharma cash? How does racism in medicine loom over Covid-19 studies? And who decides when a clinical trial goes on pause?
15 Loka 202028min
Episode 132: How Trump's case of Covid-19 affects biotech, medicine, and the FDA with George Scangos
Why is the president making drug ads? Are antibodies the new vaccines? And is it ethical for doctors to talk about President Trump's health?
8 Loka 202023min
Episode 131: Saad Omer on Covid-19 vaccine trials, & Ethan Weiss on intermittent fasting
Can an itchy arm ruin a clinical trial? Does intermittent fasting work? And is pharma more trustworthy than the CDC?
1 Loka 202025min
Episode 130: A road map for Covid-19, the gold rush in health tech, & D.C.'s pandemic unrest
Is superspreading an Olympic event? Will Covid-19 forever change health tech? And what are the limits of Anthony Fauci's patience?
24 Syys 202025min
Episode 129: Heidi Tworek on pandemic PR, plus the CDC's credibility crisis & a lightning round
How should governments talk about Covid-19? Can the Centers for Disease Control and Prevention rebuild public trust? And when is a steak worth $21 billion?
17 Syys 202026min
